For safety reasons, when imipramine use is linked to higher risks in individuals with depression and underlying liver disease, it is recommended that serum AST and ALT be regularly monitored during clinical trials despite the fact that no such recommendation has been formally made for related investigations. This evidence concerns the gene GPT and depressive symptom measurement.